Antibody Drug Conjugates Market 2030: What Will Be Changes In Investment Ratio With Opportunity Anal

Author : Mrudula Karmarkar | Published On : 29 Jan 2024

San Francisco, 29 January 2024: The Report Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology ({Type-Cleavable, Non-cleavable}), By Region, And Segment Forecasts, 2023 - 2030

The global antibody drug conjugates market size is expected to reach USD 22.35 billion by 2030, registering a CAGR of 11.2% over the forecast period, according to a new report by Grand View Research, Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products. For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer. Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Additionally, in March 2022, ImmunoGen, Inc. announced the submission of biological license application (BLA) to the U.S. FDA for mirvetuximab soravtansine used as monotherapy in patients with ovarian cancer. It comprises alpha-binding antibody, cleavable linker, and the maytansinoid DM4 as payload to kill the targeted cancer cells.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage. For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021. The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Request sample report of Antibody Drug Conjugates Market@ https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market/request/rs1

The market is primarily driven by rising incidence of cancer globally. According to Cancer Research UK estimates the number of new cancer cases worldwide is expected to reach 27.5 million by 2040. Factors such as smoking, unhealthy diet, obesity, and alcohol are the major cause of rising cancer cases worldwide. The COVID-19 pandemic had a negative impact on the product sale due to loss of health insurance coverage, decrease in hospital visits, and lower diagnosis rates. Unavailability of participants for clinical trial studies led to delay in potential approval of antibody drug conjugates (ADC)s such as Adcetris for other indications.

Antibody Drug Conjugates Market Report Highlights

• Breast cancer dominated the market for the largest revenue share of 50.61% in 2022, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer
• Cleavable linker segment accounted for largest revenue share of 65.20% in 2022 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology
• Based on linker Technology Type, others segment dominated the market due to presence of a large number of highly effective linkers in market such as SMCC, SPP, MCC, maleimide tetrapeptide, CL2A, and MC (Maleimidocaproyl) used to deliver payloads to their target sites.
• North America dominated the market in terms of revenue share of 53.29% in 2022 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs

Increasing investment in this field by key players such as Piramal Pharma Solution, Pfizer Inc., Seagen Inc., and F. Hoffman La-Roche Ltd for the development of new ADCs for the treatment of cancer is anticipated to drive market growth. For instance, in February 2022, CDMO Piramal Pharma Solutions (PPS) invested about USD 74.6 million for the development of two new antibody-drug conjugates (ADC) production facilities at its existing sites of Grangemouth, Scotland to fulfil the growing demand for commercial ADCs in UK. This investment strengthens PPS’ position in the market significantly increasing ADC manufacturing capacity.

Most of the companies are conducting clinical trials to bring new products to the market and to gain label expansion for their already approved products. For instance, in January 2022, Seagen initiated phase 1 clinical trials of two novel antibody-drug conjugates such as SGN-B7H4V & SGN-PDL1V in patients with advanced solid tumors. In addition, the company in collaboration with Astellas completed enrollment of patients for cohort K EV-103 trial for the treatment of First-Line Metastatic Urothelial Cancer (mUC). Successful completion of the clinical trial study and subsequent approval of products is anticipated to drive market growth.

Breast cancer accounted for the largest revenue share of 50.61% in 2022 owing to relatively high prevalence of the disease worldwide. According to WHO, worldwide there were around 2.26 million new breast cancer cases diagnosed in 2020 and estimated deaths due to cancer were 685,000. There are three antibody-drug conjugate products available for the treatment of breast cancer as; Trodelvy from Gilead Sciences, Inc.; Enhertu from AstraZeneca; and Kadcyla from Hoffmann-La Roche Ltd. Providing these drugs under patient assistance program is expected to drive market growth. Kadcyla offers financial assistance to eligible patients who are publicly & commercially insured.

Antibody Drug Conjugates Market Report Scope

The leading players are focusing on growth strategies, such as innovations in the existing product, approval of new products, licensing agreements, and mergers & acquisitions to gain market share. For instance, in March 2023, AstraZeneca completed a licensing agreement with KYM Biosciences for CMG-901. It is a potential ADC being evaluated in a phase 1 clinical trial currently and targets Claudin 18.2, a promising target for gastric cancer.

List of Key Players in the Antibody Drug Conjugates Market

• Seagen, Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• Daiichi Sankyo Company Limited
• GlaxoSmithKline plc
• Astellas Pharma, Inc.
• ADC Therapeutics SA